GH Research Ireland Ltd, a Dublin, Ireland-based clinical-stage biopharmaceutical company, closed a $125m Series B financing.
The round was co-led by RA Capital and RTW Investments, LP, with participation from existing investor BVF Partners, and new backers Acuta Capital Partners, Boxer Capital, Cormorant Asset Management, Deerfield Management Company, Logos Capital, Surveyor Capital (a Citadel company), Venrock Healthcare Capital Partners and Verition Fund Management.
Founded in 2018, GH Research Ireland develops novel therapies for the management of psychiatric and neurological disorders. The company’s lead product, GH001, is an innovative drug product for 5-MeO-DMT administration via a proprietary inhalation approach. GH001 has completed a Phase 1 healthy volunteer clinical trial, where administration of GH001 was observed to be well-tolerated, and a dose range and individualized dosing regimen was also defined. GH001 is currently being investigated in an ongoing Phase 1/2 clinical trial in patients with Treatment-Resistant Depression. The company’s goal is to administer GH001 in a single-day individualized dosing regimen that enables patients to achieve a rapid and durable remission with convenient administration.
GH Research Ireland plans to advance GH001 into clinical development in additional psychiatric and neurological disorders beyond Treatment-Resistant Depression. The company also plans to advance GH002, its injectable 5-MeO-DMT product candidate, into clinical development, as well as explore additional drug delivery approaches.